Table 2.
Clinical-pathological characteristics and XBP1 and CD44 staining in 62 patients with PCNS-DLBCL
| Variable | Subgroup | No | XBP1 (%) | CD44 (%) | χ | P value |
|---|---|---|---|---|---|---|
| APVT | Positive | 54 | 47 (87) | 42 (78) | ||
| Negative | 8 | 2 (33) | 2 (33) | 13.848 | .0031 | |
| RPVI | Positive | 20 | 1 (8) | 5 (25) | ||
| Negative | 42 | 30 (73) | 35 (84) | 26.7697 | <.0001 | |
| IELSG prognosis score | Low | 13 | 4 (37) | 3 (25) | ||
| Intermediate | 23 | 17 (75) | 18 (81) | |||
| High | 26 | 20 (79) | 22 (86) | 15.0494 | .0199 | |
| Primary treatment | Radiotherapy | 31 | 16 (52) | 26 (84) | ||
| Chemotherapy | 57 | 45 (80) | 46 (82) | 4.4402 | .2177 | |
| High-dose methotrexate | Yes | 28 | 19 (70) | 21 (76) | ||
| No | 34 | 24 (71) | 27 (81) | 0.1168 | .989 |
Abbreviations: APVT, aggregative perivascular tumor cell; IELSG, International Extranodal Lymphoma Study Group; RPVI, reactive perivascular T cell infiltrate.